Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dare Bioscience Inc

DARE
Current price
0.37 USD +0.011 USD (+3.06%)
Last closed 0.36 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 35 286 436 USD
Yield for 12 month -60.75 %
Week
Month
Year
DARE
21.11.2021 - 28.11.2021

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder; and DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy. The company's Phase I-ready products are DARE-VVA1, a proprietary formulation of tamoxifen for intravaginal to treat vulvar vaginal atrophy in women with hormone-receptor positive breast cancer; DARE-PDM1, a proprietary hydrogel formulation of diclofenac, a nonsteroidal anti-inflammatory drug, for vaginal administration as a treatment for dysmenorrhea; DARE-204 and DARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-GML, an intravaginally-delivered potential multi-target antimicrobial agent formulated with glycerol monolaurate; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal healt Address: 3655 Nobel Drive, San Diego, CA, United States, 92122

Analytics

WallStreet Target Price

4.2 USD

P/E ratio

Dividend Yield

Current Year

+10 000 000 USD

Last Year

Current Quarter

+1 000 000 USD

Last Quarter

Current Year

+10 000 000 USD

Last Year

Current Quarter

+1 000 000 USD

Last Quarter

Key Figures DARE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -41 959 984 USD
Operating Margin TTM -839.64 %
PE Ratio
Return On Assets TTM -69.6 %
PEG Ratio
Return On Equity TTM -341.28 %
Wall Street Target Price 4.2 USD
Revenue TTM 1 000 000 USD
Book Value -0.023 USD
Revenue Per Share TTM 0.012 USD
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM 9 900 000 USD
Earnings Share -0.48 USD
Diluted Eps TTM -0.48 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics DARE

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History DARE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:10
Payout Ratio
Last Split Date 20.07.2017
Dividend Date 20.07.2017

Stock Valuation DARE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 21.1912
Price Sales TTM 35.2864
Enterprise Value EBITDA -0.505
Price Book MRQ 3.4443

Financials DARE

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators DARE

For 52 weeks

0.28 USD 1.4 USD
50 Day MA 0.41 USD
Shares Short Prior Month 577 328
200 Day MA 0.77 USD
Short Ratio 1.43
Shares Short 446 972
Short Percent 0.46 %